» Articles » PMID: 38017652

Tumor-infiltrating Immune Cell Score As an Independent Prognostic Predictor for Endometrial Carcinoma: Insights from a Comprehensive Analysis of the Immune Landscape

Overview
Specialty Oncology
Date 2023 Nov 29
PMID 38017652
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immune cells are crucial components in the tumor microenvironment and have a significant impact on the outcomes of patients.

Aims: Here, we aimed to establish a prognostic score based on different types of tumor-infiltrating immune cells for Endometrial Carcinoma (EC).

Methods And Results: We enrolled and analyzed 516 EC patients from The Cancer Genome Atlas. The relative abundance of 22 immune cells were estimated by using the CIBERSORTx algorithm. Cox regression was performed to identify potential prognostic immune cells, which were used to develop a Tumor-infiltrating Immune Cell Score (TICS). The prognostic and incremental value of TICS for overall survival were compared with traditional prognostic factors using the C-index and decision curves. Clustering analysis using all immune cells identified three immune landscape subtypes, which had weak correlation with survival. A TICS was constructed using CD8T cells, resting memory CD4 T cells, activated NK and activated DCs, and classified patients as low-, moderate- and high-risk subgroups. The low-risk subgroup had higher tumor mutation burden and activation of IL2/STAT5, IL2/STAT3 and IFN-gamma response pathways. Conversely, the high-risk subgroup was associated with DNA copy number variation, hypoxia and EMT process. The TICS subgroups significantly predicted overall survival, which was independent of patient age, tumor stage, grade and molecular classification. Moreover, we developed a nomogram incorporating TICS and clinicopathologic factors, which significantly improved the predictive accuracy compared to the clinicopathologic model alone.

Conclusion: The TICS is an effective and independent prognostic predictor for EC patients and may serve as a useful supplement to clinicopathological factors and molecular subtyping.

Citing Articles

Single-cell RNA sequencing in endometrial cancer: exploring the epithelial cells and the microenvironment landscape.

Gonzalez-Martinez S, Perez-Mies B, Cortes J, Palacios J Front Immunol. 2024; 15:1425212.

PMID: 39229264 PMC: 11368840. DOI: 10.3389/fimmu.2024.1425212.


Tumor-infiltrating immune cell score as an independent prognostic predictor for endometrial carcinoma: Insights from a comprehensive analysis of the immune landscape.

Zhang L, Zhu Q, Zhao Q, Lin X, Song H, Liu H Cancer Rep (Hoboken). 2023; 7(1):e1939.

PMID: 38017652 PMC: 10809205. DOI: 10.1002/cnr2.1939.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Golia DAuge T, Cuccu I, Santangelo G, Muzii L, Giannini A, Bogani G . Novel Insights into Molecular Mechanisms of Endometrial Diseases. Biomolecules. 2023; 13(3). PMC: 10046407. DOI: 10.3390/biom13030499. View

3.
Bell D, Ellenson L . Molecular Genetics of Endometrial Carcinoma. Annu Rev Pathol. 2018; 14:339-367. DOI: 10.1146/annurev-pathol-020117-043609. View

4.
Chen Y, You S, Li J, Zhang Y, Kokaraki G, Epstein E . Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification. Front Immunol. 2022; 12:788959. PMC: 8777298. DOI: 10.3389/fimmu.2021.788959. View

5.
Cuccu I, DOria O, Sgamba L, De Angelis E, Golia DAuge T, Turetta C . Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives. Healthcare (Basel). 2023; 11(4). PMC: 9957190. DOI: 10.3390/healthcare11040571. View